Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.53 |
| ▸ | GSK3A | P49840 | 5/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 3/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4335983 | 0.86 | MEN1 (0.51) | GSK3BGSK3AMAPK14ABL1CDK2 | |
| SCHEMBL4334963 | 0.86 | MEN1 (0.51) | GSK3BGSK3AMAPK14ABL1CDK2 | |
| SCHEMBL4333014 | 0.85 | GSK3B (0.65) | GSK3BGSK3APIK3CDPIM1PIK3CA | |
| SCHEMBL2863485 | 0.85 | CDK4 (0.46) | GSK3BCDK2ITK | |
| SCHEMBL4336796 | 0.82 | GSK3B (0.49) | GSK3BGSK3AMAPK14ABL1PIK3CD | |
| SCHEMBL4329381 | 0.82 | MAPK10 (0.59) | GSK3BGSK3APIK3CDPIM1PIK3CA | |
| SCHEMBL2871320 | 0.82 | PDPK1 (0.66) | GSK3BMAPK14PDPK1ITK | |
| SCHEMBL13927689 | 0.81 | CHEK1 (0.48) | GSK3BGSK3AABL1PIK3CDPIM1 | |
| SCHEMBL4338506 | 0.79 | GSK3B (0.50) | GSK3BGSK3AMAPK14ABL1PDPK1 | |
| SCHEMBL4340833 | 0.79 | SMN1; SMN2 (0.47) | MAPK14ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | GSK3B 991/4885GSK3A 1159/4885MAPK14 4/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | GSK3B 991/4885GSK3A 1159/4885MAPK14 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.